Execution risk in product approvals for Pune facility
Ramp-up of SPL Infusion depends on obtaining approvals for 23-24 products; delays could impact revenue targets.
SANJIVANIPARANTERAL / bear-case history
Track the concerns that keep returning.
Sanjivani Paranteral · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
Margin volatility from product mix shifts
Management acknowledged that quarterly margins can fluctuate due to product mix, which may affect predictability.
Geopolitical and logistics disruptions
Past logistics issues due to geopolitical tensions have been resolved, but any recurrence could impact export shipments.
Low promoter shareholding
An analyst raised concern about promoter shareholding being low; management indicated gradual increases but no specific target.
Geopolitical Disruption in Middle East
US-Iran conflict disrupted shipping routes and export logistics in March 2026, impacting Q4 revenue. Management has found alternative routes but risks remain.
Input Cost Inflation
Raw material and packing input costs increased in March 2026 due to crude oil price volatility and supply chain disruptions. Management expects some margin pressure.
IV Facility Product Approval Delays
Product approvals for the Pune IV plant have been slower than expected due to government process delays. Only 5 products approved out of 23 planned.
Receivable Days Volatility
Receivables have increased significantly compared to FY24 levels. Management attributes this to sales growth and customer payment terms, but it remains a risk.